Comparison of the new Mycofast Revolution assay with a molecular assay for the detection of genital mycoplasmas from clinical specimens by unknown
RESEARCH ARTICLE Open Access
Comparison of the new Mycofast Revolution
assay with a molecular assay for the detection of
genital mycoplasmas from clinical specimens
Mathys J Redelinghuys1*†, Marthie M Ehlers1,2†, Andries W Dreyer1,2†, Hennie A Lombaard3 and Marleen M Kock1,2†
Abstract
Background: Genital mycoplasmas are opportunistic bacteria that are associated with undesirable gynaecologic
and reproductive events. Mycoplasmas are fastidious bacteria with increasing resistance to routine antimicrobials
and often fail to grow on conventional culture methods. The commercial Mycofast Revolution assay permits the
phenotypic detection and identification of genital mycoplasmas. Antimicrobial susceptibility testing against five
antimicrobial agents with MICs corresponding to the CLSI guidelines can also be performed. This study aimed to
compare the new commercially available Mycofast Revolution assay with a multiplex PCR assay.
Methods: Self-collected swabs were obtained from pregnant women attending the antenatal clinic of a tertiary
academic hospital in Pretoria, South Africa from October 2012 to November 2012. These swabs were used to seed
UMMt and modified Amies transport media. The seeded UMMt transported medium was used to inoculate the
Mycofast Revolution assay for the identification, enumeration and antimicrobial susceptibility testing of genital
mycoplasmas. Following DNA extraction from the modified Amies transport medium, specimens were subjected to
a multiplex PCR assay for the detection of genital mycoplasmas.
Results: The Mycofast Revolution kit had a sensitivity and specificity of 77.3% (95% CI: 62.15% to 88.51%) and 80%
(95% CI: 28.81% to 96.70%), respectively, against the PCR assay. The positive and negative predictive values were
97.1% (95% CI: 85.03% to 99.52%) and 28.6% (95% CI: 8.57% to 58.08%). Genital mycoplasmas were detected in
71.4% (35/49) of samples with the Mycofast Revolution assay with 49% (24/49) being Ureaplasma spp. and 22.4%
(11/49) mixed strains. The multiplex PCR assay had a positivity rate of 89.8% (44/49) for genital mycoplasmas; mixed
strains were present in 51% (25/49) of samples, Ureaplasma spp. in 16.3% (8/49) and M. hominis in 22.4% (11/49) of
samples.
Conclusions: There was a fair agreement (κ = 0.319) between the Mycofast Revolution assay and the mPCR assay.
With the high prevalence rates of genital mycoplasmas, fast and efficient diagnostic methods are imperative to
treat infections and minimise complications. The Mycofast Revolution assay is simple to use, has a short turn-
around time and interpretation of results are straightforward. This assay circumvents common problems
experienced with conventional culture and molecular methods in diagnostic laboratories where skilled personnel
are limited and can be used as an alternative diagnostic assay.
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Background
Genital mycoplasmas, including Mycoplasma genitalium,
M. hominis and Ureaplasma spp. are potentially patho-
genic bacteria that frequently colonise the genitourinary
system of sexually active individuals [1]. Infections by
these bacteria can lead to genital infections as well as
undesirable sequelae during pregnancy [2,3]. The chal-
lenge of conventional methods to diagnose mycoplasmas
forces researchers to investigate more sensitive, reliable
and rapid alternatives. Susceptibility testing becomes
prominent in the background of widespread antimicro-
bial resistance and topographical variation and must be
incorporated in these testing systems.
Bacterial resistance to routine antimicrobial agents is a
growing and worldwide problem. The lack of a rigid cell
wall renders genital mycoplasmas innately resistant to
antimicrobial agents, such as β-lactam antibiotics and
vancomycin [4]. General treatment options include agents
like tetracyclines and fluoroquinolones [5]. Fluoroquino-
lone antimicrobial agents can be used to treat genital
mycoplasma infections caused by strains that are resistant
to agents, such as the tetracycline agent doxycycline [6].
Agents that are frequently used include ofloxacin, cipro-
floxacin, levofloxacin, gemifloxacin and moxifloxacin [7].
Moxifloxacin is a more recent quinolone, which has the
highest in vitro activity against genital mycoplasmas [7].
These agents interact with the DNA gyrase and topoisom-
erase IV of bacteria [8]. Accordingly, fluoroquinolone re-
sistance is associated with mutations in the gyrA and gyrB
genes and the parC and parE genes [9]. Tetracyclines and
fluoroquinolones are the drugs of choice, yet these agents
are contraindicated in pregnancy [10,11]. During preg-
nancy, macrolides like erythromycin are often used [1,11].
Strains of M. hominis have natural resistance to C14
and C15 macrolides (e.g. clarithromycin, erythromycin,
azithromycin and roxithromycin), while Ureaplasma spp.
are resistant to lincosamides like clindamycin [12,13].
Resistance of Ureaplasma spp. to macrolides is widely
reported and is associated with mutations in the 23S
rRNA gene [14,15]. Tetracycline resistance is found
in no less than 10% of Ureaplasma strains and ap-
proximately 40% of these resistant strains demon-
strate cross-resistance to erythromycin [16]. Increased
resistance to tetracyclines in Ureaplasma spp. and M.
hominis is associated with the presence of the move-
able tet(M) genetic element, the solitary tetracycline
resistance mechanism, which renders ribosomes re-
sistant to this agent [17,18].
Phenotypic and genotypic methods for the identifica-
tion of mycoplasmas are available. Culture is still
regarded as the gold standard for the detection of recov-
erable bacteria like M. hominis and Ureaplasma spp.;
however, a low sensitivity when compared to polymer-
ase chain reaction (PCR) assays has been reported
[19,20]. Culture is labour intensive and time consuming
as it requires the use of an enrichment broth for up to
seven days, followed by sub-culturing on solid media.
Analytical sensitivities in the range of 60% are only
obtained in skilled laboratories and identification is re-
stricted to the genus level. The development of com-
mercially available diagnostic assays, which are based on
liquid broth cultures provide easy to use and faster al-
ternatives to conventional culture methods for the de-
tection of genital mycoplasmas [21]. The difficulty of
laboratory culture methods to isolate M. genitalium
complicates antimicrobial susceptibility testing [22].
There is currently no approved commercially available
diagnostic assay for the detection and antimicrobial re-
sistance testing of M. genitalium; detection is mainly
done by nucleic acid amplification tests (NAATs) [23].
The new commercially available Mycofast Revolution
(ELiTech Diagnostic, France) assay is a CE approved assay
(European Conformity; A mandatory European marking
for certain product groups to indicate conformity with the
essential health and safety requirements set out in
European Directives). This assay provides easy identifica-
tion and enumeration of M. hominis and/or Ureaplasma
spp. within 24 h to 48 h [24]. The Mycofast Revolution
assay is a liquid method based on the ability of Urea-
plasma spp. and Mycoplasma hominis to metabolize urea
and arginine, respectively and consists of 20 wells that are
pre-coated with a dehydrated culture medium (foal serum,
yeast extract, cysteine, arginine, urea, phenol red and
antibiotics) and contains a single broth with antimicrobials
for transport and preservation of genital mycoplasmas
(UMMt) (ELiTech Diagnostic, France). The Mycofast
Revolution assay includes an additional screening tray,
which can be used prior to inoculation to differentiate be-
tween positive and negative specimens and is much more
cost-effective. The screening tray and test trays allow the
detection of genital mycoplasmas at concentrations ≤103
colour change units per millilitre (ccu/ml) and >103 ccu/
ml, respectively.
Other commercially available diagnostic assays that
are similar with regards to genital mycoplasma identi-
fication, antimicrobial susceptibility testing, turn-
around time and ease of use include the Mycoplasma
Duo kit (Sanofi Diagnostics Pasteur, France), the
Mycoview (Ivagen) and MycoIST2 (BioMérieux) test
kits [14,25]. The advantage of the Mycofast Revolu-
tion assay is that antimicrobial susceptibility testing is
performed against different antimicrobial agents with
specific minimum inhibitory concentrations (MICs) as
defined by the 2011 Clinical and Laboratory Stan-
dards Institute (CLSI) guidelines. Antimicrobial sus-
ceptibility testing is performed against five antimicrobial
agents that include levofloxacin, moxifloxacin, erythro-
mycin, clindamycin and tetracycline [24].
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Molecular methods, such as PCR assays are reported to
be more sensitive for diagnostic purposes than culture [26].
Waites et al. [26] indicated that PCR-positive, culture-
negative specimens are likely to represent true positives
due to the much higher sensitivity. Genotypic methods
also allow for speciation, which is a limitation of culture
[26]. Other advantages include rapid detection as well
as that these assays do not rely on the viability of the
bacterium for detection [27]. Furthermore, when using
a multiplex PCR (mPCR) assay, the detection of more
than one target in a single reaction is possible and this
can simplify the workflow [28].
The new commercially available Mycofast Revolution
assay may have the potential to be used as a simplified
and cost effective method to diagnose genital mycoplas-
mas. The purpose of the study was to compare the
Mycofast Revolution assay with an mPCR assay for the
detection of genital mycoplasmas from clinically col-
lected vaginal specimens.
Methods
The study was conducted at the Department of Medical
Microbiology, University of Pretoria from October 2012
to November 2012. Ethical approval was obtained from
the Student Research Ethics Committee of the Univer-
sity of Pretoria prior to commencement of the study
(Approved protocol number: S6/2012). The study popu-
lation included pregnant women attending the antenatal
clinic at a tertiary academic hospital in Pretoria, Gauteng,
South Africa. The inclusion criteria of participants in this
study were pregnant women attending the antenatal clinic
who were older than 18 years and who gave written
informed consent. All non-pregnant women, pregnant
women younger than 18 years or pregnant women who
did not give written informed consent were excluded from
this study.
Two self-collected vaginal swabs (Copan Diagnostics,
Inc, Italy) were obtained from fifty pregnant women. The
order in which the swabs were obtained was randomised
between patients. After collection, a dry Rayon swab was
used to seed 3 ml transport (UMMt) medium of the
Mycofast Revolution assay; the second swab (a flocked
nylon swab) was inoculated into 1 ml of modified Amies
transport medium (Copan Diagnostics, Inc, Italy) and
used for PCR analysis. Inoculated media and reagents
used were stored at 2°C to 8°C, whereas consumables were
stored at room temperature (±25°C). The inoculated
modified Amies transport medium was stored at −20°C
until DNA extraction was performed (within ±2 weeks of
specimen collection). Extracted DNA was stored at −20°C
until PCR analysis (done within ±1 week after DNA
extraction).
The swabs and the transport media were processed
according to the manufacturer’s instructions. Briefly,
100 μl of seeded UMMt medium was added to the M.
hominis (MH) and U. urealyticum (UU) wells of the
Mycofast Screening Revolution tray with an additional
50 μl of MH supplement (S.Mh) added to the MH well.
The wells were covered with two drops of sterile mineral
oil and the tray was incubated (Vacutec, South Africa) at
37°C ± 1°C for 24 h. After incubation, the wells were ob-
served for any colour changes. Orange or red colour
changes indicated the presence of M. hominis and/or
Ureaplasma spp., whereas yellow wells marked the ab-
sence of mycoplasmas. In the case of a positive screening
test, the excess UMMt medium that was stored at 2°C to
8°C was used to inoculate the Complement Mycofast
Revolution tray. Wells 1 to 20 were filled with 100 μl of
seeded UMMt medium, wells 6 to 7 filled with an add-
itional 50 μl of S.Mh and all the wells were covered with
two drops of mineral oil. The tray was incubated (Vacutec,
South Africa) at 37°C ± 1°C for 24 h (maximum 48 h in
all cases) and after incubation observed for colour changes
similar to that of the screening tray. Mycoplasma hominis
(MH) identification wells contained erythromycin to in-
hibit the growth of Ureaplasma spp., while the UU wells
contained lincomycin to inhibit the growth of M. hominis.
The specific breakpoints (in μg/mL) indicating suscep-
tibility (S) or resistance (R) for Ureaplasma spp. are as
follow [24]: levofloxacin S ≤ 2, R ≥ 4; moxifloxacin S ≤ 2;
erythromycin S ≤ 8, R ≥ 16; tetracycline S ≤ 1, R ≥ 2. The
breakpoints for M. hominis are as follow: levofloxacin
S ≤ 1, R ≥ 2; moxifloxacin S ≤ 0.25; clindamycin S ≤ 0.25,
R ≥ 0.5; tetracycline S ≤ 4, R ≥ 8. Strains were regarded as
resistant when growth was inhibited by the higher crit-
ical concentration of the antimicrobial agent, but not the
lower critical concentration or when growth was not
inhibited by either the higher or lower critical concen-
trations of the antimicrobial agents.
Specimens were subjected to a human β-globin PCR
assay to serve as an internal control and monitor pos-
sible PCR inhibitors. The mPCR assay used was done
according to Stellrecht et al. [29] but in multiplex
format with the following modifications: 40 PCR cycles
and primers at final concentrations of 0.2 μM with the
Qiagen multiplex PCR kit (Qiagen, Germany). This
method was previously compared to the gold standard
(culture on A7 agar) for genital mycoplasma identifica-
tion and showed good sensitivity, specificity and positive
and negative predictive values (87%, 96%, 94% and 93%,
respectively) for the detection of genital mycoplasmas
[29]. The mPCR assay was conducted with primers
targeting genes specific for M. genitalium, M. hominis,
U. parvum and U. urealyticum [29]. Oligonucleotide
primers were synthesised by Inqaba Biotechnical Indus-
tries, South Africa. The mPCR assay was validated with
AmpliRun Mycoplasma genitalium DNA control (Vircell
SL, Spain), a positive M. hominis specimen isolated with
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A2 agar and reference strains ATCC 27813 (U. parvum)
and ATCC 27619 (U. urealyticum).
Statistical analysis was performed using the PCR assay
as the gold standard to calculate the sensitivity, specificity,
positive predictive value and negative predictive value of
the Mycofast Revolution assay. The positivity rates of both
assays were determined and the agreement between the
two methods was determined by the kappa (κ) statistic.
The κ value, a measure of test reliability, was interpreted
as follows: < 0.2, poor; 0.21 to 0.4, fair; 0.41 to 0.6, moder-
ate; 0.61 to 0.8, good; ≥ 0.81, excellent [30].
Results
A total of 49 samples were included in this study. Con-
tamination was observed in one specimen (2%) that was
excluded from the analysis. The number of specimens
that tested positive and negative with the Mycofast
Revolution (phenotypic) and the mPCR (genotypic) as-
says as well as the breakdown according to species are
displayed in Table 1.
Genital mycoplasmas were detected in 71.4% (35/49)
of samples with the Mycofast Revolution assay. Forty-
nine percent (24/49) of cultures were positive for Urea-
plasma spp., while none of the cultures were positive for
only M. hominis. Mixed strains (M. hominis and Urea-
plasma spp.) were present in 22.4% (11/49) of cultures.
Mixed strains were determined when the identification
wells of both M. hominis and Ureaplasma spp. gave
positive results. Mycoplasmas were not detected in
28.6% (14/49) of specimens. One sample was positive
with the Mycofast Revolution assay but negative with
the mPCR assay.
Ureaplasma spp. were resistant to levofloxacin and
moxifloxacin in 42% (10/24) and 4% (1/24) of cases, re-
spectively (Table 2). Ureaplasma spp. had susceptibilities
of 25% (6/24) and 21% (5/24) to erythromycin and tetra-
cycline, respectively. The resistance patterns for mixed
isolates were similar to those of Ureaplasma spp., except
for erythromycin and tetracycline to which 100% (11/11)
of the isolates were resistant.
The mPCR assay detected genital mycoplasmas in 89.8%
(44/49) of specimens. Ureaplasma spp. were detected in
16.3% (8/49), while M. hominis was detected in 22.4% (11/
49) of specimens. Fifty-one percent (25/49) of specimens
were positive for both Ureaplasma spp. and M. hominis.
The mPCR assay results showed only 10.2% (5/49) of
specimens to be negative.
Statistical analysis, when considering the mPCR assay
as the gold standard, showed a sensitivity and specificity
of 77.3% (95% CI: 62.15% to 88.51%) and 80% (95% CI:
28.81% to 96.70%), respectively for the Mycofast Revolu-
tion assay to detect genital mycoplasmas. The positive
and negative predictive values were 97.1% (95% CI:
85.03% to 99.52%) and 28.6% (95% CI: 8.57% to 58.08%),
respectively. The kappa statistic was 0.319.
Discussion
This study is the first to compare the Mycofast Revolu-
tion commercial assay against an mPCR assay for the
detection of genital mycoplasmas from clinical speci-
mens in South Africa. There was a fair agreement
(κ = 0.319) between the results of the phenotypic and
genotypic methods. The Mycofast Revolution assay
showed a high sensitivity and specificity, of 77% and 80%
respectively, considering it only detects viable bacteria.
However, this contributed to a low negative predictive
value (28.6%) when the mPCR assay was considered the
gold standard.
The positivity rates reported in this study are high
(71% for the Mycofast Revolution and 91.8% for the
mPCR assays). A study by Bayraktar et al. [31] in pregnant
women, including symptomatic and asymptomatic control
patients, reported a prevalence of 29% for genital myco-
plasmas. A Greek study (2009) reported a prevalence of
37% in outpatient women with clinical vaginitis [32]. Both
of these studies identified genital mycoplasmas with the
Table 1 Results of M. hominis and Ureaplasma spp. after the Mycofast Revolution and mPCR assay analyses (n = 49)
Assay M. hominis (MH)1
No (%)
Ureaplasma spp. (UU + UP)1
No (%)
Mixed isolation: MH + (UU + UP)
No (%)
Negatives No (%) Total
Mycofast Revolution 0 24 (49) 11 (22.4) 14 (28.6) 49
PCR 11 (22.4) 8 (16.3) 25 (51) 5 (10.2) 49
1Where MH is M. hominis, UP is U. parvum and UU is U. urealyticum.
Table 2 The distribution (%) of Ureaplasma spp. and M. hominis at different breakpoints of antimicrobial agents
(n = 49)
Levofloxacin Moxifloxacin Erythromycin Clindamycin Tetracycline
11 2 4 0.25 2 8 16 0.25 0.5 1 2 4 8
Ureaplasma species (n = 24) 50 29 13 88 4 71 4 0 100 17 25 4 33
Ureaplasma species and M. hominis (n = 11) 73 18 9 82 9 9 91 0 100 9 18 9 64
1The breakpoints in μg/mL according to the CLSI guidelines24.
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commercially available Mycoplasma IST-2 kit. Govender
et al. screened low-risk antenatal patients in South Africa
at their first antenatal visit (16 to 23 weeks’ gestation) for
mycoplasmas at two different time frames (2003 and
2005) [3]. This research group used an mPCR assay and
documented prevalence rates of genital mycoplasmas of
almost 80% and around 40% in 2003 and 2005, respect-
ively [3]. Nonetheless, the type of assay may have an effect
on the accurate detection of genital mycoplasmas, de-
pending on the growth factors and antimicrobial agents
included in the media of the commercial assay.
A higher detection rate was observed for Ureaplasma
spp. (detected alone in 24% of specimens) compared to
M. hominis (never detected alone) with the Mycofast
Revolution assay. The opposite was true for the mPCR
assay with M. hominis being detected more frequently
(detected alone in 22.4% of specimens, 6.1% more than
the single detection of Ureaplasma spp.). The reason for
the higher detection rate by the mPCR assay could be
ascribed to specimens containing a low concentration of
bacteria that were not detected after 48 h with the
Mycofast Revolution assay. In such cases, the presence
of genital mycoplasmas may possibly be colonisation in-
stead of infection as the Mycofast Revolution assay is
designed to detect whether the pathological threshold
was reached.
A limitation of the Mycofast Revolution assay is that a
low concentration of M. hominis may result in random
wells to turn positive. Nonetheless, a specimen would
only be regarded as positive if the identification wells are
positive and the pathological thresholds are reached.
The Mycofast Revolution assay does not distinguish be-
tween the species, U. parvum and U. urealyticum and
analysis with additional molecular methods is needed for
speciation. The specimen which tested positive with the
Mycofast Revolution assay but negative with the PCR
assay was neither re-extracted nor repeated with a PCR
assay.
Although PCR assays have the advantage of being
sensitive, it remains costly and is dependent on skilled
personnel. The inoculation and handling of the Mycofast
Revolution assay do not require skilled personnel and
the results are easy to interpret. In addition, the Mycofast
Revolution assay allows quantitation of the number of
mycoplasmas present and gives an indication of colonisa-
tion or infection. Despite the lower observed sensitivity of
the Mycofast Revolution assay compared to the mPCR
assay, the main advantage of the Mycofast Revolution
assay is that it tests the activity of a variety of new anti-
microbial agents against genital mycoplasmas with
updated MICs as defined by the 2011 CLSI guidelines
[24]. This may reduce the cost of antimicrobial surveil-
lance and renders the Mycofast Revolution assay of clin-
ical importance in the era of increasing antimicrobial
resistance. The Mycofast Revolution assay may be an ac-
ceptable assay to use in routine diagnostic laboratories in
South Africa where resources are limited. It may be used
as an alternative in laboratories where insensitive conven-
tional culture methods are used.
The difference in the findings between the two assays
can be ascribed to numerous factors, including different
bacterial loads on the different swabs, the viability of
bacteria and the difference in analytical sensitivities of
the two assays. A limitation of the study was that an
additional molecular assay was not used to resolve the
discrepancies between the two assays.
Conclusions
The Mycofast Revolution assay could be considered as a
cost-effective alternative to conventional culture methods
for the rapid detection of genital mycoplasmas. The assay
may allow laboratory personnel to provide the clinician
with a result in a short period (± 48 hours) of time to-
gether with antimicrobial susceptibility data. Antimicro-
bial susceptibility patterns are vital as successful treatment
will depend on the early administration of effective anti-
microbial agents. In pregnant women it is particularly im-
portant to reduce these infections to prevent adverse
pregnancy outcomes.
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